Compare TRNS & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRNS | MRVI |
|---|---|---|
| Founded | 1964 | 2014 |
| Country | United States | United States |
| Employees | N/A | 416 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.5M | 890.9M |
| IPO Year | 1995 | 2020 |
| Metric | TRNS | MRVI |
|---|---|---|
| Price | $88.86 | $5.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $116.00 | $4.13 |
| AVG Volume (30 Days) | 178.4K | ★ 3.1M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $331,877,000.00 | $185,743,000.00 |
| Revenue This Year | $21.75 | $12.54 |
| Revenue Next Year | $7.55 | $7.87 |
| P/E Ratio | $156.19 | ★ N/A |
| Revenue Growth | ★ 19.20 | N/A |
| 52 Week Low | $50.23 | $1.99 |
| 52 Week High | $94.76 | $6.55 |
| Indicator | TRNS | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 69.95 |
| Support Level | $86.10 | $3.27 |
| Resistance Level | $94.48 | N/A |
| Average True Range (ATR) | 3.75 | 0.32 |
| MACD | -0.58 | 0.05 |
| Stochastic Oscillator | 28.98 | 69.98 |
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.